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Abstract
Background: The objective of this study is to identify the critical formulation parameters controlling distribution
and function for the rectal administration of microbicides in humans. Four placebo formulations were designed
with a wide range of hydrophilic characteristics (aqueous to lipid) and rheological properties (Newtonian, shear
thinning, thermal sensitive and thixotropic). Aqueous formulations using typical polymers to control viscosity were
iso-osmotic and buffered to pH 7. Lipid formulations were developed from lipid solvent/lipid gelling agent binary
mixtures. Testing included pharmaceutical function and stability as well as in vitro and in vivo toxicity.
Results: The aqueous fluid placebo, based on poloxamer, was fluid at room temperature, thickened and became
shear thinning at 37°C. The aqueous gel placebo used carbopol as the gelling agent, was shear thinning at room
temperature and showed a typical decrease in viscosity with an increase in temperature. The lipid fluid placebo,
myristyl myristate in isopropyl myristate, was relatively thin and temperature independent. The lipid gel placebo,
glyceryl stearate and PEG-75 stearate in caprylic/capric triglycerides, was also shear thinning at both room
temperature and 37°C but with significant time dependency or thixotropy. All formulations showed no rectal
irritation in rabbits and were non-toxic using an ex vivo rectal explant model.
Conclusions: Four placebo formulations ranging from fluid to gel in aqueous and lipid formats with a range of
rheological properties were developed, tested, scaled-up, manufactured under cGMP conditions and enrolled in a
formal stability program. Clinical testing of these formulations as placebos will serve as the basis for further
microbicide formulation development with drug-containing products.
Background
Over 33 million people were living with HIV worldwide
in 2007, including 2.5 million people newly infected; 2
million people died of AIDS-related illnesses [1]. Recep-
tive anal intercourse (RAI) is common in populations
worldwide. In a multicenter AIDs cohort study, unpro-
tected RAI, accounting for nearly all new HIV infections
among the homosexual men enrolled in this study, is
the riskiest sexual act that results in HIV infection [2].
According to Sigma Research in 2006, 89.3% of gay and
bisexual men engaged in rectal intercourse at least once,
58.2% engaging in both insertive anal intercourse and
RAI [3]. Despite knowing that condoms can prevent
HIV transmission, large numbers of uninfected women
and men practice sex without condoms [4] even with
HIV-infected partners.
Rectal microbicides offer both primary protection
against HIV in the absence of condoms and back-up
protection when condoms fail [5]. Until now, microbi-
cide research has been focused on vaginal use; the only
Phase 1 rectal microbicide clinical trial uses a vaginal
microbicide formulation [6,7]. However there are signifi-
cant physiological differences between the rectal and
vaginal compartments. Rectal epithelium is much thin-
ner and more fragile, provides a greater surface area for
infection, contains a greater number of CD4+ cells, and
tissue adsorption is enhanced by lymphatic circulation.
The relative enormity of the colon in comparison to the
more limited size of the vaginal cavity is another pro-
blem. In addition, vaginal microflora is predominately
Lactobacilli with acidic pH 4-5, while that of the rectum
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is predominantly anaerobic gram negative and gram-
positive bacteria with minimal buffering capacity of neu-
tral pH 7-8. Rectal toxicity associated with products
containing nonoxynol-9 (N-9) [8-11] have been
reported.
Personal lubricants are commonly used during anal
intercourse [12,13]; some are not safe to use with fragile
rectal tissue. Fuchs, et al. [14] evaluating the effects of
marketed vaginal lubricants applied rectally found that
hyper-osmolar gels caused rectal epithelial damage by
inducing epithelia denudation and luminal secretion.
Recent studies by Hendrix, et al. [15] have established the
potential for semen and gel product distribution as high
as the splenic flexure following simulated anal inter-
course. These studies illustrate that the target surface for
protection using a rectal microbicide may be quite large.
These considerations require site-specific formulation
strategies for the development of safe and effective rectal
microbicide products. Romano, et al. [16] have reviewed
and outlined global strategies, Patton, et al. [17] has
“outlined specific criteria” for preclinical rectal efficacy
trials and Garg, et al. [18,19] have summarized prefor-
mulation and formulation from a pharmaceutics
approach. However, to date, the ideal functional charac-
teristics for a rectal microbicide have yet to be
identified.
This study is part of a multi-center rectal microbicide
development program designed in part to elucidate
these functional characteristics [20]. The specific objec-
tive of this study is to develop a series of placebo formu-
lations with a wide range of physical/chemical properties
anticipated to be critical in rectal microbicide deploy-
ment and subsequently, in a separate human clinical
study, evaluated for distribution and safety. The func-
tional characteristics resulting from these two studies
will form the basis for formulation development of a
rectal microbicide for administration of water soluble or
water insoluble active antiviral drugs, as single entities
or, in combination.
Results
Baseline Data for Rectal Lubricants
Since personal lubricants are widely used during RAI, a
series of marketed products were evaluated to identify a
baseline of physical characteristics that might contribute
to the placebo design. A sampling of the lubricant pro-
ducts was obtained on the open market covering the
three basic types of lubricants, aqueous based, lipid
based, and silicone based; these are listed in Table 1.
Nine lubricants were evaluated for physical properties.
The rheological profiles of all the semisolid lubricants
were non-Newtonian; the aqueous semisolids were pseu-
doplastic (shear thinning) while the lipid based semisolids
were pseudoplastic with thixotropy. The liquid lubricants,
both silicone and the aqueous based, all exhibited Newto-
nian behavior. On a comparative basis, viscosities of the
lubricants (Table 1) ranged from 145 cps to 7810 cps at
25°C, 751 to 7810 cps for aqueous based lubricants, 1810
to 5790 cps for lipid based lubricants and less than 200
cps for the silicone based lubricants. The viscosity of the
aqueous and the silicone lubricants were lower at 37°C
than at 25°C but this was not significant. However, the
lipid based semisolid lubricants, exhibited a highly signifi-
cant temperature effect with up to a 9 fold decrease in
viscosity between 25°C and 37°C.
The osmolalities of the aqueous lubricants varied from
2510 ± 26 to 6110 ± 90 mmol/kg, all of which were
highly hyperosmolar. The pH values of the aqueous
lubricants range from 4 to 5.5.
Condom/lubricant compatibility using the puncture
strength test showed that in both groups of lubricated
and non-lubricated condoms, water had a strengthening
effect (p = 0.05) while mineral oil deteriorated condom
integrity significantly (p = 0.05) overtime. The four aqu-
eous gel lubricants tested, Astroglide (BioFilm, Inc.,
Vista, Ca), Anal Lube (California Exotic Novelties LLC.,
Chino, CA), ID Glide (ID Lubricants, Notts, NG UK),
and K-Y Gelly (Personal Products Company, Skillman,
NJ), had a strengthening effect on both lubricated and
non-lubricated condoms when compared with the nega-
tive control; the effect was either equivalent to the con-
trol at 15 minutes or significantly increased puncture
strength at 30 minutes. The lipid lubricants showed var-
ied results. ID cream (ID Lubricants, Notts, NG, UK)
showed the same degree of deterioration as mineral oil;
however, the other two lipid based lubricants, Boy but-
ter (Eyal Feldman, BBL LLC, CA) and Elbow grease (B.
Cumming Company, Sun Valley, CA) were compatible
with the condoms. For two silicone based lubricants,
Gun oil (Empowered Products, Inc., Las Vegas, NV) and
Wet Platinum (WET International, Valencia, CA), the
effect on puncture strength was somewhat strengthening
but less than water with the latter exhibiting a time
dependent effect on lubricated condoms.
Initial Placebo Design Parameters
Two fundamentally different approaches to establishing an
effective rectally administered microbicide are possible;
creating a formulation that spreads easily and coats all tis-
sue surfaces of the rectum and distal colon rapidly prior to
RAI or creating a deformable, erodible barrier that would
remain relatively localized at the administration site until
distributed by rectal intercourse. Accepting this premise
and taking the results from the personal lubricants into
account, we suggest that both aqueous and non-aqueous
based formulations could be acceptable with target viscos-
ities of < 200 cps and >5000 cps for the fluid and gel for-
mulations, respectively. Aqueous formulations would be
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iso-osmotic with a pH of 7 and all formulations would be
compatible with latex condoms. This suggests the follow-
ing categories of formulations:
I. Aqueous Formulations:
a. Fluid - easily spreadable
b. Gel - erodible
II. Lipid Formulations:
a. Fluid - easily spreadable.
b. Gel - erodible
Fluid formulations would have a viscosity consistent with
rapid rectal/colonic distribution while the distribution of
gel formulations would be instigated by rectal intercourse.
Aqueous Placebo Design
Prototype aqueous formulations were prepared with one
of two polymers, which represent a range of chemical
structures, as the viscosity or gelling agent, carbopol
974, poloxamer 407. Formulations ranging from fluids
to gels were created by varying the concentration of
polymer and were placed on stability at ambient tem-
perature and 40°C. Viscosity, visual appearance and pH
were followed over a period of 3 months.
Lipid Placebo Design
The development of the lipid formulations presented a
greater challenge considering the lack of lipid formulations
in the vaginal or rectal market. Binary mixtures of lipid
solvents and lipid gelling agents were screened for com-
patibility; the results of which are summarized in Table 2.
Lipid solvents were selected to represent different chemi-
cal classes: triglycerides, fatty acid esters and POE fatty
acid esters. Silicones, although not chemically lipids, were
included as common non-aqueous lubricants. Lipid gelling
agents were selected on a similar basis: fatty alcohols, fatty
acid esters, glycerol fatty acid esters and POE fatty acids.
Binary mixtures were prepared by fusion at concentra-
tion levels of gelling agent (generally from 0.5% to 40%) to
achieve a viscosity range from fluid to gel and placed on
storage at 22°C and 40°C. An antioxidant was added to
mixtures containing unsaturation, i.e. liquid fatty acids or
triglycerides. Viscosity and visual appearance were followed
over a period of 3 months. Compatibility was defined as
complete miscibility during preparation and the absence of
phase separation or precipitation during storage at either
ambient or 40°C. As shown in Table 2, 14 out of a total of
36 mixtures tested were initially compatible; however, only
two were stable enough to be considered further.
Final Placebo Selection
Following the three month stability period formulations
were evaluated for physical appearance and stability
leading to the selection of the final four placebos listed
in Table 3. The selection process also considered the
ease of manufacture anticipating eventual scaling up to
Table 1 Properties of selected commercial rectal lubricants
Osmolalitya Viscosityb Gel strengtha Adhesiona Condom Compatibilityd
Product Type pH mmol/kg cps mN mN•sec Lubricated Non-lubricated
25°C 37°C 15 Min 30 Min 15 Min 30 Min
Water based
Astroglide Liquid 4 6110 ± 90 204.08 180.5 <4.9 NRc 39.9↑ 42.5↑ 49.9↑ 11.0↑
Anal Lube Gel 5.5 3530 ± 20 6700 6190 14.9 ± 0.5 196.0 ± 19.6 22.4↑ 17.1↑ 40.3↑ 42.0↑
ID Glide Gel 5.2 3150 ± 2 751 601 <4.9 NR 26.8↑ 33.5↑ 51.3↑ 49.8↑
K-Y Jelly Gel 4.5 2510 ± 26 7810 6560 14.9 ± 0.3 215.6 ± 19.6 52.7↑ 46.6↑ 49.3↑ 34.2↑
Lipid based
ID cream Cream NR NR 1810 212 39.2 ± 2.0 42.1 ± 2.9 -45.0↓ -48.5↓ -25.9↓ -37.1↓
Boy Butter Cream NR NR 4840 2600 34.3 ± 2.9 59.8 ± 2.9 20.4↑ 25.2↑ 40.2↑ 42.7↑
Elbow Grease Original Cream NR NR 5790 906 98.0 ± 9.8 58.8 ± 9.8 13.9↑ 4.9↑ 40.9↑ 40.8↑
Silicone based
Gun Oil Liquid NR NR 175 138 NR NR 10.5↑ 15.8↑ 20.9↑ 22.5↑
Wet Platinum Premium Liquid NR NR 145 113 NR NR 13.4↑ -18.6↓ 7.8↑ 7.4↑
Water (negative control) 22.3↑ 20.2↑ 14.8↑ 15.3↑
Mineral oil (positive control) -46.6↓ -59.2↓ -51.1↓ -56.3↓
a Reported as average (n = 3) of triplicate measurements.
b Reported as average of duplicate measurements.
c NR, testing not required.
d Condom compatibility is expressed as percent change in puncture strength of treated vs untreated condoms.
↔ No significant difference (p = 0.05).
↑ Treated sample significantly greater than untreated (p = 0.05).
↓ Treated sample significantly less than untreated (p = 0.05).
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clinical size batches. An effort was also made to select
formulations composed of a range of chemical struc-
tures, i.e., no duplication of solvents or gelling agents.
Placebo Properties and Stability
The physical properties for the final four placebo formu-
lations are summarized in Table 4; the stability data for
12 months at 25°C/60% RH and 6 months at 40°C/75%
RH were all within testing specifications. Considering
FDA guidelines regarding stability predictions, the 40°C
data would support a shelf life in excess of two years [21].
Rheological Profiles
The rheological profile of the aqueous gel placebo exhibits
shear thinning and nonNewtonian pseudoplastic behavior
(Figure 1A) with typical decrease in viscosity with an
increase in temperature; similar to most of the commercial
aqueous based semisolid personal lubricants evaluated.
The lipid gel placebo (Figure 1C) exhibits similar shear
thinning behavior with the addition of significant thixotro-
pic or time-dependent character as evidenced by the hys-
teresis loop between the up curve and down curve.
The rheological profiles of the aqueous and lipid fluid
placebos (Figure 1B and 1D) are Newtonian at 25°C, i.e.
the viscosity is constant over the entire shear rate range.
However, the aqueous fluid placebo exhibits a degree of
nonNewtonian and shear thinning behavior at 37°C. The
lipid fluid placebo, on the other hand, shows very little
decrease in viscosity with an increase in temperature
resulting in a formulation that maintains a relatively
constant viscosity under anticipated use conditions.
Condom Compatibility
Condom compatibility was evaluated using a puncture
strength test developed in house for rapid screening of a
large number of formulations as well as standard ASTM
Table 2 Compatibility of binary lipid solvent/lipid gelling agent mixtures
Gelling agent
Solvent Stearyl
alcohol
Glyceryl
tribemate
Myristyl
myristate
Cetyl
esters
Cetyl
alcohol
Hydrogenated palm/palm
kernel oil PEG-6 esters
Glyceryl stearate
PEG-75 stearate
Olive oil - B1a C1 - - - -
Capric/Caprylic
triglycerides
- B2a,b,d,e C2a - E2 F2a G2a,b,c,d,e
Ethyl oleate A3 - C3a D3 E3 F3a G3a
Isopropyl myristate A4 - C4a,b,c,d,e D4 E4 F4 G4a
Caprylocaproyl
macrogol-8 glycerides
A5a B5 C5 D5 E5a F5a,b,d,e G5
Silicone oil (350-500cs) A6 B6 - - E6 F6 G6a,b,d,e
Cyclomethicone A7 B7 - - E7 F7 G7
a Potential miscible combinations used for further study. Miscible combinations can be obtained from stage of liquid to semisolid by varying the concentration
level of gelling agent from 0-40%.
b Stable combinations at least at one concentration level of gelling agent at room temperature.
c Stable combinations at least at one concentration level of gelling agent at both room temperature and 40°C.
d Rectal tissue explant toxicity were evaluated and showed nontoxic.
e Condom compatibility studies showed compatible with both non-lubricated and lubricated condoms.
- Not tested.
All others: incompatible combinations. Two phases upon made or short term storage at room temperature.
Table 3 Formulas for the four rectal microbicide placebos
Fluid Gel
Ingredient Weight(%) Ingredient Weight(%)
Poloxamer 407 15 Carbopol 974P 0.5
Glycerin 2 Glycerin 2.5
Aqueous Methylparaben 0.18 Methylparaben 0.18
Propylparaben 0.02 Propylparaben 0.02
Trisodium Citrate Dihydrate 0.3 Disodium EDTA 0.1
Purified water 82.5 Sodium Hydroxide solution (18% w/v) 1.15
Purified Water 95.55
100 100
Isopropyl Myristate 5 Glyceryl Stearate and PEG-75 Stearate 25
Lipid Myristyl Myristate 95 Caprylic/Capric Triglyceride 74.9
Vitamin E Acetate 0.1
100 100
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method, which includes airburst volume, airburst pres-
sure, tensile break force and elongation.
To develop the puncture strength method, a number
of marketed product comprising water based, lipid
based and silicone based products were evaluated (table
1). These studies confirmed that ID cream and Wet Pla-
tinum premium were incompatible with condoms as
suggested on their marketed labels. The puncture
strength test clearly differentiates between the aqueous
and mineral oil controls (a range of 15% to 22% and
-47% to -59% respectively, see Tables 1 and 4).
According to the puncture strength test, all aqueous
placebo formulations show a degree of compatibility
with lubricated and non-lubricated condoms. With
respect to the lipid products, potential incompatibility
with lubricated condoms was predicted. However,
incompatibility with non lubricated condoms was not
identified. With respect to the lipid gel studies with
lubricated condoms (Table 4) the puncture strength test
showed a 0.95% and -6.1% change compared to non
treated lubricated condoms(for the 15 and 30 minute
test conditions respectively), significantly different from
the results of all the other cases.
Testing of the four placebo products using the ASTM
method showed both of the lipid products failed to meet
the acceptance criteria when tested with non-lubricated,
silicone lubricated and aqueous lubricated condoms. The
lipid formulations, however, did meet acceptance criteria
with polyurethane condoms. The aqueous products were
found to be condom compatible.
Although the puncture strength test did not comple-
tely agree with the standard ASTM condom test results
for the two lipid formulations, it was able to identify
condom incompatibilities in marketed products and sug-
gested potential incompatibility with the lipid gel. This
suggests that the puncture strength test can be a useful
screening tool for rapid assessment of large numbers of
formulations to eliminate those with highest potential
for condom incompatibilities. However, full condom
compatibility evaluation utilizing the ASTM method
should be conducted on final formulations identified for
advancement.
Rectal Toxicity Assessment
Using polarized colorectal explant cultures, N-9 was a
positive control and showed a reduction of viability to
21.4% of the control, untreated explants. The lipid gel
was 140% ± 64, the lipid fluid was 105% ± 26, the aqu-
eous gel was 122% ± 66, and the aqueous gel was 122%
± 39 of the control, untreated explants. The non-toxic
nature of the four formulations was confirmed by histol-
ogy showing no alteration of the epithelium.
Using a rabbit rectal irritation model, the four placebo
formulations had no significant damage at the rectal site
of administration, no mortality occurred during the
study and no clinical abnormalities or significant find-
ings were observed. Gross pathology at necropsy pro-
vided no evidence for tissue damage or inflammation of
the rectum or surrounding tissues. Collectively, these
results support each other showing the safety of the rec-
tal placebo formulations.
Table 4 Physical properties of the four rectal microbicide placebos
Viscositya Gel
Strength b
Adhesionb Osmolarity Condom Compability
(puncture strength)
Product Appearance cps pH Lubricated Non-
lubricated
Standard ASTM
method
25°
C
37°
C
mN mN•sec mmol/kg 15
Min
30
Min
15
Min
30
Min
Lipid Gel* White, creamy, rigid semi-
solid
5634 2719 196.0 ± 2.0 127.4 ±
13.9
NR NR 0.95
↑
-6.1↔ 32.8
↑
25.8
↑
Fail
Lipid
Fluid*
Clear, colourless, easily
spreadable liquid
5 4 NRc NR NR NR 23.0
↑
23.6
↑
26.5
↑
25.0
↑
Fail
Aqueous
Gel*
Transparent colourless gel 5613 5225 21.3 ± 0.2 31.9 ± 7.8 324 ± 15 7.2 33.8
↑
30.1↑ 18.8
↑
27.5
↑
Pass
Aqueous
Fluid*
transparent colourless liquid 94 4136 NR NR 402 ± 8 7.0 39.9
↑
32.9
↑
21.0
↑
22.3
↑
Pass
Water (negative control) 22.3
↑
20.2
↑
14.8
↑
15.3
↑
Mineral Oil (positive control) -46.6
↓
-59.2
↓
-51.0
↓
-56.3
↓
a Reported as average of duplicate measurements.
b Reported as average ± SD(n = 3) of triplicate measurements.
c NR, testing not required.
*passed microbial limit tests.
↔ No significant difference (t-test, p = 0.05).
↑ Treated sample significantly greater than untreated (t-test, p = 0.05).
↓ Treated sample significantly less than untreated (t-test, p = 0.05).
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Microbiological Testing
All formulations passed the USP Microbial Limits test.
In addition, the aqueous formulations passed the USP
Antimicrobial Effectiveness Test.
Scale-up and GMP Manufacturing
The four placebo formulations were successfully scaled-
up to a clinical batch size of 8 kg, were manufactured
under cGMP conditions at DPT Laboratories, San Anto-
nio, TX and placed on a formal stability program. The
stability program will continue until the conclusion of
planned clinical studies.
Discussion
The initial placebo design attempted to consider two
basic concepts, placebo performance as a drug delivery
vehicle and the rectal delivery of a drug in such a for-
mulation. The first concept was addressed by creating
formulations that would include ready spreading and
coating all tissue surfaces of the rectum and distal colon
rapidly prior to RAI and alternately, formulations that
would present a deformable, erodible barrier that would
remain relatively localized at the administration site
until distributed by rectal intercourse. With these con-
cepts in mind and taking the results from the personal
lubricants into account, representing a measure of prac-
tical acceptance, our work suggests that both aqueous
and non-aqueous based formulations could be accepta-
ble for the rectal administration of a microbicide.
The rheological properties designed in the placebos pro-
vide the clinician with a choice of physical performance.
A. Aqueous Gel
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Figure 1 Rheological profiles of the four rectal microbicide placebos. The aqueous gel (1A) exhibits pseudoplastic behavior, the aqueous
fluid (1B) exhibits Newtonian behavior, the lipid gel (1C) is thixotropic, and the lipid fluid (1D) is Newtonian.
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The aqueous gel placebo with shear thinning and non-
Newtonian pseudoplastic behavior and typical decrease in
viscosity with an increase in temperature compares with
most of the commercial aqueous based semisolid personal
lubricants evaluated. Viscosity recovery on cessation of
shear induced by rectal intercourse would be instanta-
neous since no thixotropic behavior is observed. The lipid
gel placebo, in contrast, exhibits similar shear thinning
behavior with the addition of significant thixotropic or
time-dependent character and as a consequence, viscosity
recovery would be slow. Fluid properties produced by rec-
tal intercourse would be maintained.
The Newtonian profiles of the aqueous and lipid fluid
placebos with constant viscosity over the entire shear
rate range would translate into efficient distribution on
application. The aqueous fluid placebo would result in
longer retention with the increase in viscosity as the for-
mulation reaches body temperature. The lipid fluid pla-
cebo, on the other hand, shows very little decrease in
viscosity with an increase in temperature resulting in a
formulation that maintains a relatively constant viscosity
under actual use conditions.
These rheological properties thus are anticipated to
have the following behavior on rectal administration
affected significantly whether rectal intercourse is pre-
sent or not.
• The lipid fluid, being relatively thin with little tem-
perature dependence, would distribute rapidly and
efficiently after rectal administration.
• The aqueous fluid, with low viscosity initially for
rapid distribution upon administration followed by
increase in viscosity at body temperature would
result in more localized retention.
• The lipid gel with high viscosity and being shear
thinning permits distribution instigated by rectal
intercourse and slow viscosity recovery permits con-
tinued distribution.
• The aqueous gel with relatively high viscosity and
being shear thinning permits distribution instigated
by rectal intercourse and rapid viscosity recovery
permits localized retention following distribution.
In regards to the second concept, i.e., the rectal deliv-
ery of antivial drugs, accommodation of either water
soluble or insoluble drug candidates was considered
relative to bioavailability. Since current antiretroviral
drugs being evaluated as microbicide candidates can be
either water soluble as is the case for the reverse tran-
scriptase inhibitor tenofovir or water insoluble as is the
case for the nonnucleoside revese transcriptase inhibi-
tors UC781 or dapivirine, both aqueous and non-aqu-
eous or lipid formulations [22] need to be developed.
This will provide for the opportunity to formulate either
drug as a solution thereby providing a high concentra-
tion gradient for microbicide release [23]. Based on the
four rectal placebo prototypes, for the aqueous formula-
tions, hydrophobic or water insoluble drug candidates
would be in suspension and hydrophilic or water soluble
drug candidates would be in solution, while for the lipid
formulations, hydrophobic drug candidates would be in
solution and hydrophilic drug candidates would be in
suspension.
The four placebo formulations are currently being
evaluated in a human clinical study for mucosal toxicity,
colo-rectal distribution, and participant acceptability.
Clinical parameters evaluated will be related to product
attributes such as viscosity, lipophilicity, spreadability,
mucoadhesive characteristics. These correlations will
ultimately lead to defining target specifications of rectal
specific microbicide products.
Conclusions
Four rectal microbicide placebo formulations were suc-
cessfully designed, developed, tested and manufactured
under cGMP conditions in anticipation of clinical eva-
luation in humans. The formulations have a wide range
of hydrophilic characters and rheological properties and
were shown to be non-toxic in both ex vivo and in vivo
testing. It is anticipated that clinical testing of these for-
mulations in humans will identify the critical formula-
tion parameters controlling distribution and function in
rectal administration. These results will serve as the
basis for future rectal microbicide formulation design.
Methods
Materials
Carbopol 974P was obtained from Noveon (Lubrizol,
Cleveland, Ohio), poloxamer 407 (Pluronic F127) from
BASF (Florham Park, NJ), glycerylstearate and PEG-75
stearate (Gelot 64), caprylocaproyl macrogol-8 glycerides
(Labrasol), and hydrogenated palm/palm kernel oil PEG-
6 esters (Labrafil M 2130 CS) obtained from Gattefosse
(Westwood, NJ), caprylic/capric triglyceride (Crodamol
GTCC), isopropyl myristate (Crodamol IM), stearyl alco-
hol (Crodacol S-95 NF), cetyl esters wax (Crodamol SS
NF), cetyl alcohol (Crodacol C-95 NF), glyceryl tribe-
mate (Syncrowax HR-c), ethyl oleate (Crodamol EO),
and myristyl myristate (Crodamol MM) obtained from
Croda (Edison, NJ). All other chemicals were obtained
from Spectrum Chemical Mfg. Corp. (New Brumswick,
NJ) and were either USP or NF grade. Ingredients were
GRAS [24,25] and/or commonly used in vaginal and
rectal products [26].
Preparation of lipid based placebo
Lipid gelling agents and lipid solvents (listed in table 2)
were mixed and dissolved in a water bath held at 65°C
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-75°C depending on the melting point of the gelling
agent. Additional excipient (Vitamin E, Vitamin E
Acetate, Butylated hydroxyanisole or Butylated hydro-
xytoluene) was then added. The solution was cooled
down to room temperature with stirring to achieve
homogeneity.
Preparation of aqueous based placebo
Different polymers (Carbopol or poloxamer) were evalu-
ated as aqueous gelling agents.
For Carbopol based gels, 2.5% glycerin, 0.18% methyl-
paraben and 0.02% propylparaben were dissolved in dis-
tilled water first by heating to 60°C. Carbopol was then
added and dissolved in the solution by agitation at room
temperature. Sodium hydroxide was added to induce
Carbopol crosslinking. Finally pH was adjusted to 7
using sodium hydroxide or hydrochloric acid.
For poloxamer based gels, 0.18% methylparaben, 0.02%
propylparaben, 2.5% glycerin and 0.1 M sodium citrate
dehydrate buffer were dissolved in distilled water. The
solution is then cooled to 4-8°C. After cooling the
thermo reversible polymer, Poloxamer 407, was added.
The mixture was then held overnight at 4-8°C for ade-
quate polymer dissolution. Finally, pH was adjusted to 7
using sodium hydroxide or hydrochloric acid.
Appearance
Samples were evaluated by visual inspection for phase
separation, color, clarity, consistency and particulates in
clear, glass scintillation vials.
Viscosity
Rheological profiles were determined using a cone and
plate viscometer (Brookfield HADV III+ and LVDV III
ultra) recording shear stress over a range of shear rates
at both increasing and decreasing shear rates, i.e. up
curve and down curve, respectively. All viscosities
reported are apparent viscosities calculated as the ratio
of shear stress to shear rate. For comparison purposes,
viscosities were calculated at a fixed shear rate of 10
rpm at 25 and 37°C.
pH
The pH of the aqueous gel formulations was measured
using a flat surface pH electrode (Beckman Coulter
Futura Flat Bulk Combination pH electrode), that of
aqueous fluid formulations using a glass pH electrode
(Accumet pH electrode).
Osmolality
The osmolality of aqueous formulations was measured
using a vapor pressure osmometer (Model # 5520,
Vescor).
Gel Strength/Adhesion
For all semisolid formulations gel strength and adhesion
were measured using the Texture Analyzer (TA.XT.Plus,
Texture Technologies Corp.) [27,28] using a smooth
surface and a ¼ inch ball probe. Gel strength is defined
as the maximum force recorded during penetration (N)
and adhesion is defined as the area under the force/dis-
tance curve on withdrawal (N•sec).
Condom Compatibility Measurement
A method utilizing the Texture Analyzer was developed
for the evaluation of condom/formulation compatibility.
Briefly, 10 condoms were exposed to a formulation for a
period of 15 and 30 minutes, washed using DI water,
dried with a paper towel, and the puncture strength or
breakpoint evaluated from the tensile/strain vs. force
curve using a 1/8” ball probe.
In addition, a standard airburst test and tensile test for
condom compatibility [29,30] (ISO-4074: 2002, ASTM
D-3492) was contracted to a third party contractor who
routinely conducts condom testing (Family Health Inter-
national, FHI, Research Triangle Park, NC).
Stability Studies
Formal stability assessments were performed according to
ICH guidance [31]. Gel products were packaged in glass
straight side jars, liquid products in glass Boston round bot-
tles with poly-seal caps and stored at 25°C/60% RH or 40°
C/75% RH. Testing intervals were 0, 1, 2, 3 and 6 months
for the samples stored at 40°C/75% RH, and 0, 1, 2, 3, 6, 9
and 12 months for the samples stored at 25°C/60% RH.
The testing included appearance, viscosity and microbial
limit test [32] for all samples plus pH, osmolality and anti-
microbial effectiveness test [33] for aqueous samples.
Microbiological Testing
Microbiological testing was performed according to the
USP30-NF25 General Chapters <61> Microbial Limit
Tests (USP 30, page 83) for all formulations.
Safety Testing Using ex vivo Polarized Colorectal Explant
Cultures
Human Tissue
Normal human colorectal (IRB # 0602024) tissue was
acquired from persons undergoing colorectal surgery for
non-inflammatory conditions through IRB approved
protocols. No patient identifiers were provided and all
tissues collected were anonymized, de-identified, unlink-
ing any patient ID to the investigators.
Explant Studies
Tissue toxicity of the test formulations was determined
using a polarized explant human colorectal culture sys-
tem [34,35]. Briefly, the explant was placed with the
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luminal side up in a transwell and the edges around the
explant were sealed with Matrigel™ (BD Biosciences,
San Jose, CA). The explants were maintained with the
luminal surface at the air-liquid interface with the
lamina propria resting on medium-soaked gelfoam. Cul-
tures were maintained at 37°C in a 5% CO2 atmosphere.
Placebo formulations were placed undiluted on the
apical side of the explants using untreated explants or a
1:5 dilution of 3% N9 gel as controls. The next day,
explants were washed and viability was evaluated using
the MTT [1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylfor-
mazan] assay and histology.
Rabbit Rectal Irritation Study
A ten day repeat dose toxicology study in New Zealand
white rabbits following rectal administration of placebo
formulations was performed by Pacific Biolabs (PBL,
Hercules, CA). General morbidity and morbidity checks
were performed twice daily for general health. Clinical
observations were performed daily. Animals were
observed for changes in their general appearance includ-
ing, but no limited to, signs of dehydration, loss of
weight, abnormal posture and hypothermia. Blood was
collected from all animals just prior to necropsy on day
11 for hematology, coagulation, and clinical chemistry
evaluations.
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